NCT02686944View on ClinicalTrials.gov

A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

May 10, 2019

Study Completion Date

May 10, 2019

Conditions
Gastrointestinal Stromal Tumor
Interventions
BIOLOGICAL

Intuvax (ilixadencel)

Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection

Trial Locations (1)

SE-171 76

Department of Breast and Endocrine Surgery, Section of Endocrine and Sarcoma Surgery, Karolinska University Hospital, Stockholm

Sponsors

Lead Sponsor

Mendus
All Listed Sponsors
lead

Mendus

INDUSTRY

NCT02686944 - A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors | Biotech Hunter | Biotech Hunter